The Data Advantage
Genomic data is the raw material of precision medicine. The more diverse the data, the more universally applicable the findings. Yet global genomic databases have historically been dominated by European ancestry populations, limiting the generalisability of research findings and creating inequities in drug development and clinical care.
Singapore’s PRECISE-SG100K cohort addresses this gap directly. By building a large-scale, multi-ancestry dataset of 100,000 Singaporeans—a population that reflects Chinese, Malay, Indian, and other ancestries—the project provides pharmaceutical companies with access to Asian genomic data under a governed framework. The Pharma Pre-competitive Consortium, which now includes five global companies, allows partners to analyse the dataset in a secure environment while generating insights into disease biology, risk factors, and treatment response relevant to Asian populations.
From Discovery to Diagnostics
Access to genomic data is necessary but not sufficient. Translating those data into clinical tools requires diagnostic platforms that can identify disease early, classify patients by likely treatment response, and monitor therapeutic efficacy. Singapore’s research institutions are developing these tools across multiple fronts.
At NUS, researchers developed a DNA “barcode” platform that rapidly screens nanoparticles for their ability to deliver therapies to specific cellular targets, including mitochondria inside cancer cells. The platform dramatically speeds up the development of precision nanomedicine by enabling high-throughput screening of delivery vehicles. Meanwhile, scientists at A*STAR identified a specific marker for gastric cancer stem cells and demonstrated that eliminating this subpopulation could prevent tumour recurrence.
These discoveries share a common logic: identify the biological target with precision, then develop the diagnostic or therapeutic tool to address it. This is the essence of precision medicine—moving away from one-size-fits-all treatments toward interventions tailored to individual patients.
Engineering Drug Discovery
The drug discovery process itself is being reshaped by Singapore’s research investments. The Experimental Drug Development Centre (EDDC) launched a collaboration with Daiichi Sankyo in March 2026 to develop next-generation NK cell engagers—molecules designed to direct the immune system’s natural killer cells against tumours while reducing systemic inflammation. NK cell engagers represent an emerging therapeutic modality that could address limitations of existing immunotherapy approaches.
In January 2026, ASTAR licensed its multicistronic expression vector technology to Callio Therapeutics, enabling high-yield production of antibody-drug candidates. This is a classic example of publicly funded research being transferred to a commercial entity for further development—a model that Singapore has refined through institutions like ASTAR’s technology transfer office.
The Clinical Translation Pipeline
The ultimate test of any biomedical research ecosystem is whether discoveries reach patients. Singapore’s clinical trial infrastructure has expanded significantly. Bristol Myers Squibb, which has conducted more than 60 clinical trials in the Asia-Pacific region, announced five new trials in Singapore starting by the end of 2026. Nuevocor, a Singapore-based gene therapy company, began its first-in-human trial in early 2026—proof that Singapore can originate, not only manufacture, innovative therapies.
These clinical activities are supported by a regulatory environment that balances rigour with efficiency, and by a healthcare system that provides access to diverse patient populations for clinical research. The integration of research hospitals, academic medical centres, and community healthcare institutions creates a continuum from discovery to delivery.
The Integrated Model
What distinguishes Singapore’s approach to precision health is its integration. Genomic data feeds into drug discovery. Diagnostic platforms identify patients for clinical trials. Clinical trial results inform regulatory submissions. Manufacturing capabilities ensure that approved therapies can be produced at scale. This end-to-end integration—from population data through to patient access—is not accidental. It reflects deliberate policy choices and sustained investment over multiple decades.
As the global biomedical industry increasingly recognises the value of diverse genomic data and integrated development capabilities, Singapore’s early investments position it as a critical node in the global precision medicine network.
